However, considering the reported efficacy and safety of targeting IL-6 in SSc-ILD patients, especially in those with an “inflammatory phenotype” suggested by elevated C-reactive protein, increased platelets counts and arthritis/tenosynovitis, tocilizumab could be considered to treat pHI in SSc patients with ILD and an inflammatory phenotype. The gene discussed is CRP; the disease is systemic sclerosis.